HC Wainwright Cuts Earnings Estimates for Connect Biopharma

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Connect Biopharma in a research note issued on Friday, October 2nd. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.32) per share for the quarter, down from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

Connect Biopharma (NASDAQ:CNTB) last released its earnings results on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. The firm had revenue of $2.75 million during the quarter, compared to analysts’ expectations of $0.74 million.

Several other equities analysts also recently weighed in on the company. Piper Sandler assumed coverage on Connect Biopharma in a research report on Friday, June 26th. They set an “overweight” rating and a $7.00 target price on the stock. Oppenheimer lowered their price target on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Weiss Ratings raised shares of Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Canaccord Genuity Group cut their price objective on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, September 16th. Finally, Wall Street Zen raised shares of Connect Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.14.

Connect Biopharma Price Performance

Shares of NASDAQ:CNTB opened at $0.94 on Tuesday. The company has a market cap of $59.49 million, a P/E ratio of -0.79 and a beta of -0.16. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. Connect Biopharma has a 52 week low of $0.85 and a 52 week high of $3.82. The business has a fifty day simple moving average of $1.83 and a 200-day simple moving average of $2.23.

Institutional Trading of Connect Biopharma

Institutional investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC acquired a new position in shares of Connect Biopharma during the first quarter worth about $1,945,000. Bank of America Corp DE purchased a new stake in shares of Connect Biopharma during the 1st quarter valued at about $41,000. Knott David M Jr raised its holdings in shares of Connect Biopharma by 93.9% during the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after buying an additional 187,835 shares during the period. Simplify Asset Management Inc. acquired a new position in Connect Biopharma during the 1st quarter worth approximately $135,000. Finally, Richmond Brothers Inc. acquired a new position in Connect Biopharma during the 4th quarter worth approximately $489,000. 58.72% of the stock is owned by hedge funds and other institutional investors.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.